{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:02:09Z","timestamp":1773792129274,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011179","name":"Cornell Feline Health Center","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100011179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006471","name":"College of Veterinary Medicine, Cornell University","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100006471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003516","name":"Winn Feline Foundation","doi-asserted-by":"publisher","award":["MT14-013"],"award-info":[{"award-number":["MT14-013"]}],"id":[{"id":"10.13039\/100003516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12917-019-1780-5","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T13:03:23Z","timestamp":1548335003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Salinomycin decreases feline sarcoma and carcinoma cell viability when combined with doxorubicin"],"prefix":"10.1186","volume":"15","author":[{"given":"Lucia","family":"Borlle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdo","family":"Dergham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zacharie","family":"Wund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Zumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Southard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-2118","authenticated-orcid":false,"given":"Kelly R.","family":"Hume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/1098612X13483235","volume":"15","author":"L Blackwood","year":"2013","unstructured":"Blackwood L. Cats with cancer: where to start. J Feline Med Surg. 2013;15:366\u201377.","journal-title":"J Feline Med Surg"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","volume":"53","author":"MM Gottesman","year":"2002","unstructured":"Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615\u201327.","journal-title":"Annu Rev Med"},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0195-5616(03)00004-4","volume":"33","author":"PJ Bergman","year":"2003","unstructured":"Bergman PJ. Mechanisms of anticancer drug resistance. Vet Clin North Am Small Anim Pract. 2003;33:651\u201367.","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1780_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2017.10.006","volume":"114","author":"V Foy","year":"2017","unstructured":"Foy V, Schenk MW, Baker K, Gomes F, Lallo A, Frese KK, Forster M, Dive C, Blackhall F. Targeting DNA damage in SCLC. Lung Cancer. 2017;114:12\u201322.","journal-title":"Lung Cancer"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1939-1676.1988.tb02794.x","volume":"2","author":"GN Mauldin","year":"1988","unstructured":"Mauldin GN, Matus RE, Patnaik AK, Bond BR, Mooney SC. Efficacy and toxicity of doxorubicin and cyclophosphamide used in the treatment of selected malignant tumors in 23 cats. J Vet Intern Med. 1988;2:60\u20135.","journal-title":"J Vet Intern Med"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5326\/15473317-36-5-416","volume":"36","author":"LG Barber","year":"2000","unstructured":"Barber LG, S\u00f8renmo KU, Cronin KL, Shofer FS. Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. J Am Anim Hosp Assoc. 2000;36:416\u201321.","journal-title":"J Am Anim Hosp Assoc"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2460\/ajvr.2000.61.791","volume":"61","author":"LE Fox","year":"2000","unstructured":"Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, MacEwen EG, Perez-Soler R, Calderwood-Mays M, Kurzman ID. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. Am J Vet Res. 2000;61:791\u20135.","journal-title":"Am J Vet Res"},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1939-1676.2002.tb02415.x","volume":"16","author":"VJ Poirier","year":"2002","unstructured":"Poirier VJ, Thamm DH, Kurzman ID, Jeglum KA, Chun R, Obradovich JE, O'Brien M, Fred RM, Phillips BS, Vail DM. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med. 2002;16:726\u201331.","journal-title":"J Vet Intern Med"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2460\/ajvr.67.3.517","volume":"67","author":"KM Rassnick","year":"2006","unstructured":"Rassnick KM, Rodriguez CO, Khanna C, Rosenberg MP, Kristal O, Chaffin K, Page RL. Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas. Am J Vet Res. 2006;67:517\u201323.","journal-title":"Am J Vet Res"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1939-1676.2007.0017.x","volume":"22","author":"WC Kisseberth","year":"2008","unstructured":"Kisseberth WC, Vail DM, Yaissle J, Jeglum KA, Couto CG, Ward H, Khanna C, Obradovich JE. Phase I clinical evaluation of carboplatin in tumor-bearing cats: a veterinary cooperative oncology group study. J Vet Intern Med. 2008;22:83\u20138.","journal-title":"J Vet Intern Med"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5829.2011.00295.x","volume":"10","author":"CF Saba","year":"2012","unstructured":"Saba CF, Vail DM, Thamm DH. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma. Vet Comp Oncol. 2012;10:283\u201391.","journal-title":"Vet Comp Oncol"},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1098612X15622237","volume":"19","author":"V Wiles","year":"2017","unstructured":"Wiles V, Hohenhaus A, Lamb K, Zaidi B, Camps-Palau M, Leibman N. Retrospective evaluation of toceranib phosphate (palladia) in cats with oral squamous cell carcinoma. J Feline Med Surg. 2017;19:185\u201393.","journal-title":"J Feline Med Surg"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-09-0096","volume":"15","author":"E Bolderson","year":"2009","unstructured":"Bolderson E, Richard DJ, Zhou BB, Khanna KK. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009;15:6314\u201320.","journal-title":"Clin Cancer Res"},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00280-010-1287-z","volume":"67","author":"LA Wittenburg","year":"2011","unstructured":"Wittenburg LA, Bisson L, Rose BJ, Korch C, Thamm DH. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin. Cancer Chemother Pharmacol. 2011;67:83\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1158\/0008-5472.CAN-11-0277","volume":"71","author":"LA Gilbert","year":"2011","unstructured":"Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res. 2011;71:5062\u20136.","journal-title":"Cancer Res"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3.","journal-title":"Clin Transl Med"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1517\/14712598.2014.918099","volume":"14","author":"L Gammaitoni","year":"2014","unstructured":"Gammaitoni L, Leuci V, Mesiano G, Giraudo L, Todorovic M, Carnevale-Schianca F, Aglietta M, Sangiolo D. Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. Expert Opin Biol Ther. 2014;14:1259\u201370.","journal-title":"Expert Opin Biol Ther"},{"key":"1780_CR19","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/0006-291X(75)90490-8","volume":"66","author":"M Mitani","year":"1975","unstructured":"Mitani M, Yamanishi T, Miyazaki Y. Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun. 1975;66:1231\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1780_CR20","doi-asserted-by":"publisher","first-page":"950658","DOI":"10.1155\/2012\/950658","volume":"2012","author":"C Naujokat","year":"2012","unstructured":"Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658.","journal-title":"J Biomed Biotechnol"},{"key":"1780_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645\u201359.","journal-title":"Cell"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.07.016","volume":"311","author":"QL Tang","year":"2011","unstructured":"Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, Xie XB, Zeng YX, Shen JN, Kang T, Wang J. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311:113\u201321.","journal-title":"Cancer Lett"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"13253","DOI":"10.1073\/pnas.1110431108","volume":"108","author":"D Lu","year":"2011","unstructured":"Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108:13253\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1780_CR24","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3892\/mmr.2015.3633","volume":"12","author":"KY Kim","year":"2015","unstructured":"Kim KY, Kim SH, Yu SN, Park SK, Choi HD, Yu HS, Ji JH, Seo YK, Ahn SC. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7\/MDR human breast cancer cells via decreased efflux of doxorubicin. Mol Med Rep. 2015;12:1898\u2013904.","journal-title":"Mol Med Rep"},{"key":"1780_CR25","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3892\/or.2015.4509","volume":"35","author":"A Hermawan","year":"2016","unstructured":"Hermawan A, Wagner E, Roidl A. Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. Oncol Rep. 2016;35:1732\u201340.","journal-title":"Oncol Rep"},{"key":"1780_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","volume":"45","author":"R Riccioni","year":"2010","unstructured":"Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, Cianfriglia M, Testa U. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010;45:86\u201392.","journal-title":"Blood Cells Mol Dis"},{"key":"1780_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s11064-016-2132-5","volume":"42","author":"SJ Zhao","year":"2017","unstructured":"Zhao SJ, Wang XJ, Wu QJ, Liu C, Li DW, Fu XT, Zhang HF, Shao LR, Sun JY, Sun BL, et al. Induction of G1 cell cycle arrest in human glioma cells by Salinomycin through triggering ROS-mediated DNA damage in vitro and in vivo. Neurochem Res. 2017;42:997\u20131005.","journal-title":"Neurochem Res"},{"key":"1780_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbrc.2009.10.042","volume":"390","author":"D Fuchs","year":"2009","unstructured":"Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390:743\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1780_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/1471-2407-13-490","volume":"13","author":"ST Liffers","year":"2013","unstructured":"Liffers ST, Tilkorn DJ, Stricker I, Junge CG, Al-Benna S, Vogt M, Verdoodt B, Steinau HU, Tannapfel A, Tischoff I, Mirmohammadsadegh A. Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas. BMC Cancer. 2013;13:490.","journal-title":"BMC Cancer"},{"key":"1780_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185\u2013229.","journal-title":"Pharmacol Rev"},{"key":"1780_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1740-8261.2002.tb01036.x","volume":"43","author":"T Kobayashi","year":"2002","unstructured":"Kobayashi T, Hauck ML, Dodge R, Page RL, Price GS, Williams LE, Hardie EM, Mathews KG, Thrall DE. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound. 2002;43:473\u20139.","journal-title":"Vet Radiol Ultrasound"},{"key":"1780_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tvjl.2004.04.004","volume":"170","author":"M Martano","year":"2005","unstructured":"Martano M, Morello E, Ughetto M, Iussich S, Petterino C, Cascio P, Buracco P. Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases. Vet J. 2005;170:84\u201390.","journal-title":"Vet J"},{"key":"1780_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2460\/javma.231.5.742","volume":"231","author":"KA Hahn","year":"2007","unstructured":"Hahn KA, Endicott MM, King GK, Harris-King FD. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989-1999). J Am Vet Med Assoc. 2007;231:742\u20135.","journal-title":"J Am Vet Med Assoc"},{"key":"1780_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2460\/javma.239.1.97","volume":"239","author":"HA Phelps","year":"2011","unstructured":"Phelps HA, Kuntz CA, Milner RJ, Powers BE, Bacon NJ. Radical excision with five-centimeter margins for treatment of feline injection-site sarcomas: 91 cases (1998-2002). J Am Vet Med Assoc. 2011;239:97\u2013106.","journal-title":"J Am Vet Med Assoc"},{"key":"1780_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2460\/javma.2000.216.58","volume":"216","author":"AE Hershey","year":"2000","unstructured":"Hershey AE, Sorenmo KU, Hendrick MJ, Shofer FS, Vail DM. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc. 2000;216:58\u201361.","journal-title":"J Am Vet Med Assoc"},{"key":"1780_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/089875641503200104","volume":"32","author":"O Bilgic","year":"2015","unstructured":"Bilgic O, Duda L, S\u00e1nchez MD, Lewis JR. Feline Oral squamous cell carcinoma: clinical manifestations and literature review. J Vet Dent. 2015;32:30\u201340.","journal-title":"J Vet Dent"},{"key":"1780_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.5326\/15473317-33-5-427","volume":"33","author":"KA Hahn","year":"1997","unstructured":"Hahn KA, Frazier DL, Cox SK, Legendre AM. Effect of infusion regime on doxorubicin pharmacokinetics in the cat. J Am Anim Hosp Assoc. 1997;33:427\u201333.","journal-title":"J Am Anim Hosp Assoc"},{"key":"1780_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bcp.2016.09.022","volume":"122","author":"JC Ko","year":"2016","unstructured":"Ko JC, Zheng HY, Chen WC, Peng YS, Wu CH, Wei CL, Chen JC, Lin YW. Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression. Biochem Pharmacol. 2016;122:90\u20138.","journal-title":"Biochem Pharmacol"},{"key":"1780_CR39","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.18632\/oncotarget.3585","volume":"6","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Liang C, Xue F, Chen W, Zhi X, Feng X, Bai X, Liang T. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the \u03b2-catenin\/TCF complex association via FOXO3a activation. Oncotarget. 2015;6:10350\u201365.","journal-title":"Oncotarget"},{"key":"1780_CR40","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1476-5381.2010.01089.x","volume":"162","author":"JH Kim","year":"2011","unstructured":"Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162:773\u201384.","journal-title":"Br J Pharmacol"},{"key":"1780_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","volume":"34","author":"SC Gupta","year":"2013","unstructured":"Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34:508\u201317.","journal-title":"Trends Pharmacol Sci"},{"key":"1780_CR42","doi-asserted-by":"crossref","unstructured":"van der Linde-Sipman JS, van den Ingh TS, Van Nes JJ, Verhagen H, Kersten JG, Beynen AC, Plekkringa R: Salinomycin-induced polyneuropathy in cats: morphologic and epidemiologic data. Vet Pathol 1999, 36:152\u2013156.","DOI":"10.1354\/vp.36-2-152"},{"key":"1780_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00109-014-1155-0","volume":"92","author":"W Boehmerle","year":"2014","unstructured":"Boehmerle W, Muenzfeld H, Springer A, Huehnchen P, Endres M. Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice. J Mol Med (Berl). 2014;92:889\u2013900.","journal-title":"J Mol Med (Berl)"},{"key":"1780_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2885.2011.01285.x","volume":"35","author":"J Henri","year":"2012","unstructured":"Henri J, Maurice R, Postollec G, Dubreil-Cheneau E, Roudaut B, Laurentie M, Sanders P. Comparison of the oral bioavailability and tissue disposition of monensin and salinomycin in chickens and turkeys. J Vet Pharmacol Ther. 2012;35:73\u201381.","journal-title":"J Vet Pharmacol Ther"},{"key":"1780_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","volume":"10","author":"Y Lai","year":"2017","unstructured":"Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10:106.","journal-title":"J Hematol Oncol"},{"key":"1780_CR46","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, et al. NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100:3175\u201382.","journal-title":"Blood"},{"key":"1780_CR47","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477\u201389.","journal-title":"J Immunol"},{"key":"1780_CR48","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Academies Press; 2011.","edition":"8"},{"key":"1780_CR49","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/vco.12195","volume":"15","author":"S Kang","year":"2017","unstructured":"Kang S, Southard T, Hume KR. DNA damage is a feature of feline injection-site sarcoma. Vet Comp Oncol. 2017;15:518\u201324.","journal-title":"Vet Comp Oncol"},{"key":"1780_CR50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12935-018-0690-0","volume":"18","author":"Y Bing","year":"2018","unstructured":"Bing Y, Wund Z, Abratte T, Borlle L, Kang S, Southard T, Hume K. Biological indicators of chemoresistance: an ex vivo analysis of \u03b3H2AX and p53 expression in feline injection-site sarcomas. Cancer Cell Int. 2018;18:192.","journal-title":"Cancer Cell Int"},{"key":"1780_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1476-5810.2006.00096.x","volume":"4","author":"SH Tannehill-Gregg","year":"2006","unstructured":"Tannehill-Gregg SH, Levine AL, Rosol TJ. Feline head and neck squamous cell carcinoma: a natural model for the human disease and development of a mouse model. Vet Comp Oncol. 2006;4:84\u201397.","journal-title":"Vet Comp Oncol"},{"key":"1780_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11626-007-9060-2","volume":"43","author":"JK Cooper","year":"2007","unstructured":"Cooper JK, Sykes G, King S, Cottrill K, Ivanova NV, Hanner R, Ikonomi P. Species identification in cell culture: a two-pronged molecular approach. In Vitro Cell Dev Biol Anim. 2007;43:344\u201351.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"1780_CR53","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1040638711408064","volume":"23","author":"LE O'Donoghue","year":"2011","unstructured":"O'Donoghue LE, Rivest JP, Duval DL. Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation. J Vet Diagn Investig. 2011;23:780\u20135.","journal-title":"J Vet Diagn Investig"},{"key":"1780_CR54","first-page":"5318","volume":"50","author":"MC Berenbaum","year":"1990","unstructured":"Berenbaum MC, Greco WR, et al. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1990;50:5318\u2013532752 4558\u20134560; author reply 4561-4555.","journal-title":"Cancer Res"},{"key":"1780_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1198\/sbr.2009.0001","volume":"1","author":"JJ Lee","year":"2009","unstructured":"Lee JJ, Kong M. Confidence intervals of interaction index for assessing multiple drug interaction. Stat Biopharm Res. 2009;1:4\u201317.","journal-title":"Stat Biopharm Res"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-1780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-019-1780-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-019-1780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T09:57:56Z","timestamp":1606125476000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-019-1780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1186\/s12917-019-1780-5","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"6 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal research was approved by the Cornell University Institutional Care and Use Committee, protocol #2011\u20130112. Written and\/or verbal consent was obtained from the owners of cats involved in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}